We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.08 | -0.29% | 27.69 | 19,231 | 11:21:21 |
From May 2019 to May 2024
By Dave Sebastian
Pfizer Inc. (PFE) reported lower fourth-quarter sales as it lost exclusivity in its pain drug Lyrica in 2019.
The New York drugmaker on Tuesday posted $12.69 billion in fourth-quarter sales, down from $13.98 billion in the prior year. Analysts polled by FactSet were expecting $12.69 billion in sales.
Sales in its Upjohn business, which includes Lyrica and anti-impotence pill Viagra, declined 32% to $2.16 billion for the quarter.
The company recorded net loss of $337 million, or 6 cents a share, compared with a loss of $394 million, or 7 cents a share, in the year-ago period.
Excluding one-time items, the company reported earnings of 55 cents a share. Analysts were looking for adjusted earnings of 58 cents a share.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
January 28, 2020 07:15 ET (12:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
